Apogee Therapeutics (APGE) Total Current Liabilities (2022 - 2026)

Apogee Therapeutics (APGE) has 5 years of Total Current Liabilities data on file, last reported at $33.0 million in Q1 2026.

• On a quarterly basis, Total Current Liabilities changed 0.02% year-over-year to $33.0 million in Q1 2026; TTM through Mar 2026 was $33.0 million, a 0.02% change from a year earlier, with the FY2025 full-year figure at $27.9 million, down 2.29% from the prior year.
• Total Current Liabilities for Q1 2026 stood at $33.0 million, up from $27.9 million in the prior quarter.
• Over the last five years, Total Current Liabilities for APGE reached as high as $34.0 million in Q3 2025 and fell as low as $10.0 million in Q4 2022.
• Historically, Total Current Liabilities has averaged $25.5 million across 5 years, with a median of $27.9 million in 2025.
• Across the five-year window, Total Current Liabilities surged 105.99% in 2023 and declined 2.29% in 2025, its largest moves.
• Year by year, Total Current Liabilities stood at $10.0 million in 2022, then jumped by 105.99% to $20.6 million in 2023, then surged by 38.92% to $28.6 million in 2024, then dropped by 2.29% to $27.9 million in 2025, then increased by 18.08% to $33.0 million in 2026.
• Per Business Quant data, the three most recent Total Current Liabilities figures were $33.0 million in Q1 2026, $27.9 million in Q4 2025, and $34.0 million in Q3 2025.